The Theme Code "非環式または炭素環式化合物含有医薬技術" had 88 patent application filings in the most recent period (2023-01-01 to 2023-03-31). This is a significantly decreased of -215 filings (-71.0%) over 303 they had in the same period of the previous year (2022-01-01 to 2022-03-31).
The highest number of filings in 2017 with 2,389 cases, and their lowest number in 2022 with 1,130 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 8,752 cases in total) is 1,459, and the median is 1,556. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 1,459 patents |
Std Dev | 668 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 1,130 cases | -21.69 % |
2021 year | 1,443 cases | -13.59 % |
2020 year | 1,670 cases | -19.98 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 非環式または炭素環式化合物含有医薬技術[4C206] for the period of the last 10 years (2014-01-01 to 2024-11-30). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 非環式または炭素環式化合物含有医薬技術, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 非環式または炭素環式化合物含有医薬技術 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
Patent landscaping is a visualization of the distribution of patent filings (application focus areas) for each technical keyword. Mountains and islands indicated by heatmap contours represent clusters of patent applications filed, and red areas on the heatmap indicate many patent filings relating to the keyword.
The patent landscape for 非環式または炭素環式化合物含有医薬技術 gives an intuitive understanding of what patent filings they have made and what technical position is to be established. By selecting filing year checkboxes and filtering, you can track their past filing trends (what technical area they have focused on).
By selecting applicant/patent holder checkboxes and filtering, you can visually grasp the technical areas of the filings for each applicant and the partnerships or alliances formed. Please use it as a guide for patent analysis and IP landscaping.
In addition, by visually representing the patent data in this manner, you can convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
In Patent Integration, you can check the specifics of a patent filing by clicking anywhere on the patent landscape screen. You can also quickly check the position of each applicant for each technical field by cross-referencing with other keywords and patent classifications. You can use it as a guide when considering hypotheses about each company's IP strategy on the IP Landscape. You can also use it for higher-grade intellectual property activities. It has reasonable pricing and a simple user interface that is easy for beginners to handle.
The following is a list of words (characteristic terms) often used in 非環式または炭素環式化合物含有医薬技術 patent applications. Characteristic terms with a higher importance are used in more patents/patent applications.
This patent analysis report was created for a patent search set of 17,680 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The patent information of the higher applicant in the technical theme 非環式または炭素環式化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
Comparing the number of applications of each company, 花王株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 28 cases, followed by 大正製薬株式会社 with 25 cases.
Name | Cases |
---|---|
花王株式会社 | 28 cases |
大正製薬株式会社 | 25 cases |
第一三共ヘルスケア株式会社 | 23 cases |
ロート製薬株式会社 | 18 cases |
小林製薬株式会社 | 15 cases |
ライオン株式会社 | 13 cases |
興和株式会社 | 8 cases |
ノバルティスアーゲー | 4 cases |
株式会社資生堂 | 3 cases |
味の素株式会社 | 1 cases |
Comparing the number of applications of each company, 小林製薬株式会社 has the highest number of joint applications in the last for the target period (2014 to 2024) with 292 cases, followed by ロート製薬株式会社 with 282 cases.
Name | Cases |
---|---|
小林製薬株式会社 | 292 cases |
ロート製薬株式会社 | 282 cases |
花王株式会社 | 201 cases |
ライオン株式会社 | 158 cases |
ノバルティスアーゲー | 146 cases |
大正製薬株式会社 | 137 cases |
興和株式会社 | 124 cases |
第一三共ヘルスケア株式会社 | 94 cases |
味の素株式会社 | 80 cases |
武田薬品工業株式会社 | 31 cases |
株式会社資生堂 | 24 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The patent information of the higher applicant in the technical theme 非環式または炭素環式化合物含有医薬技術 is shown below. By comparing the number of patents of each company, you can check the research and development status of each company's past and present technical themes and the position of each company in the technical theme.
among the top coapplicants, 花王株式会社 has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 28 cases, followed by 大正製薬株式会社 with 25 cases.
among the top coapplicants, ロート製薬株式会社 has the highest number of joint applications in the last for the target period (2014 to 2024) with 282 cases, followed by 花王株式会社 with 201 cases.
Below is a ranking of the number of JP patent applications by 非環式または炭素環式化合物含有医薬技術’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 非環式または炭素環式化合物含有医薬技術’s top 7 coapplicants over the last 20 years.
非環式または炭素環式化合物含有医薬技術 filed 137 joint applications with 大正製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 61 cases in total) is 10.2, and the median is 11.0. The coefficient of variation (standard deviation/mean) is 0.24, and there have been small fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 24 cases, and their lowest number in 2019 with 6 cases.
Index | Value |
---|---|
Average | 10.2 patents |
Std Dev | 2.5 |
COV | 0.24 |
Year | Cases | YOY |
---|---|---|
2022 year | 12 cases | -7.69 % |
2021 year | 13 cases | +8.33 % |
2020 year | 12 cases | +100 % |
非環式または炭素環式化合物含有医薬技術 filed 201 joint applications with 花王株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 113 cases in total) is 18.8, and the median is 21.5. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2017 with 36 cases, and their lowest number in 2016 with 10 cases.
Index | Value |
---|---|
Average | 18.8 patents |
Std Dev | 7.8 |
COV | 0.4 |
Year | Cases | YOY |
---|---|---|
2022 year | 22 cases | +57.1 % |
2021 year | 14 cases | -33.3 % |
2020 year | 21 cases | -16.00 % |
非環式または炭素環式化合物含有医薬技術 filed 146 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 61 cases in total) is 10.2, and the median is 5.5. The coefficient of variation (standard deviation/mean) is 1.0, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 26 cases, and their lowest number in 2021 with 2 cases.
Index | Value |
---|---|
Average | 10.2 patents |
Std Dev | 10.0 |
COV | 1.0 |
Year | Cases | YOY |
---|---|---|
2022 year | 4 cases | +100 % |
2021 year | 2 cases | -71.4 % |
2020 year | 7 cases | -69.6 % |
非環式または炭素環式化合物含有医薬技術 filed 158 joint applications with ライオン株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 71 cases in total) is 11.8, and the median is 10.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2017 with 35 cases, and their lowest number in 2022 with 9 cases.
Index | Value |
---|---|
Average | 11.8 patents |
Std Dev | 6.6 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -10.00 % |
2021 year | 10 cases | -23.08 % |
2020 year | 13 cases | +18.18 % |
非環式または炭素環式化合物含有医薬技術 filed 282 joint applications with ロート製薬株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 131 cases in total) is 21.8, and the median is 12.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2018 with 48 cases, and their lowest number in 2022 with 9 cases.
Index | Value |
---|---|
Average | 21.8 patents |
Std Dev | 16.6 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -10.00 % |
2021 year | 10 cases | -28.57 % |
2020 year | 14 cases | -66.7 % |
The following shows JP patents held by 非環式または炭素環式化合物含有医薬技術 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 非環式または炭素環式化合物含有医薬技術’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 非環式または炭素環式化合物含有医薬技術 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 17 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.7 times. The most recently Invalidation Trial patent is 特許6995822 "DPP IVインヒビターの使用" (Invalidation Trial day 2024-06-25) , next is 特許7174020 "経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療" (Invalidation Trial day 2024-05-31) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許6995822 | DPP IVインヒビターの使用 | 2024-06-25 |
2 | 特許7174020 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-05-31 |
3 | 特許7258832 | 多発性硬化症を処置するためのS1P受容体モジュレーター | 2024-05-08 |
4 | 特許6811203 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-04-24 |
5 | 特許6556767 | DPP−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 2024-03-19 |
6 | 特許4417865 | 5−アミノレブリン酸リン酸塩、その製造方法及びその用途 | 2024-03-15 |
7 | 特許6290627 | メトホルミン治療に不適切な患者における糖尿病の治療 | 2024-02-29 |
8 | 特許6143809 | DPPIVインヒビターの使用 | 2024-02-29 |
9 | 特許6262023 | 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 | 2024-01-31 |
10 | 特許6189374 | 糖尿病療法 | 2024-01-31 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 5 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 2.2. The most invalidation trial patent is 特許6445123 "癌を治療するための方法及び組成物" (5 times) , and the next most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6445123 | 癌を治療するための方法及び組成物 | 5 times |
2 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
3 | 特許6143809 | DPPIVインヒビターの使用 | 2 times |
4 | 特許6189374 | 糖尿病療法 | 1 times |
5 | 特許6556767 | DPP−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 1 times |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 20 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7425560 "固形製剤の製造方法" (Opposition day 2024-07-22) , next is 特許7366515 "外用組成物" (Opposition day 2024-04-23) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7425560 | 固形製剤の製造方法 | 2024-07-22 |
2 | 特許7366515 | 外用組成物 | 2024-04-23 |
3 | 特許7342338 | 乳酸菌と脂肪酸を含む飼料及び組成物 | 2024-03-11 |
4 | 特許7317256 | 集中力及び/又は情報処理能力の向上剤 | 2024-01-25 |
5 | 特許7282155 | 頭皮用外用組成物 | 2023-11-24 |
6 | 特許7270996 | 美容組成物 | 2023-11-10 |
7 | 特許7308329 | GABAを有効成分とするサルコペニア予防または改善剤 | 2023-10-26 |
8 | 特許7231197 | 医薬用錠剤 | 2023-08-29 |
9 | 特許7223501 | 経口組成物 | 2023-08-15 |
10 | 特許7202492 | O/D型乳化組成物 | 2023-07-11 |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 183 patents Protest from third parties. The average number of Protest is 1.8 times. The most recently Protest patent is 特開2023-038107 "脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤" (Protest day 2024-11-13) , next is 特開2022-183421 "プロスタグランジンE2産生抑制皮膚外用剤" (Protest day 2024-11-07) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特開2023-038107 | 脂質合成抑制剤及びこれを含む飲食品、脂質合成抑制用加工食品並びに発現抑制剤 | 2024-11-13 |
2 | 特開2022-183421 | プロスタグランジンE2産生抑制皮膚外用剤 | 2024-11-07 |
3 | 再公表2019/026992 | クロルヘキシジンを含有する医薬組成物 | 2024-11-01 |
4 | 特開2020-066592 | 水性貼付剤 | 2024-10-30 |
5 | 特開2022-076151 | 変色が抑制された経口組成物及びその変色抑制方法 | 2024-10-25 |
6 | 特開2021-151223 | マイオカイン産生促進剤、筋出力増強剤、および筋芽細胞の分化促進剤 | 2024-10-18 |
7 | 特開2022-100719 | 認知機能における作業記憶向上用組成物 | 2024-10-17 |
8 | 特開2024-061831 | 抗疲労剤 | 2024-10-11 |
9 | 特開2023-033865 | 口腔用組成物 | 2024-10-04 |
10 | 特開2022-021943 | 外用組成物、マスク製剤 | 2024-10-03 |
11 | 特開2021-052742 | 難水溶性物質含有製剤 | 2024-10-02 |
12 | 特開2021-052708 | アンジオテンシン変換酵素阻害剤 | 2024-09-28 |
13 | 特表2023-514396 | 抗菌組成物 | 2024-09-27 |
14 | 特開2021-011469 | 新規軟膏剤 | 2024-09-20 |
15 | 特表2023-535067 | ヒトにおける呼吸器疾患の治療及び/又は予防のためのβ-ヒドロキシブチレート及び関連化合物の投与 | 2024-09-18 |
16 | 特開2020-158493 | パンテノールを含有する油中水型(W/O型)クリーム | 2024-09-18 |
17 | 特開2022-128970 | 健康増進作用のある組成物 | 2024-09-17 |
18 | 特開2024-096254 | 骨代謝改善剤 | 2024-09-11 |
19 | 特開2021-070643 | 筋肉量改善用組成物 | 2024-09-05 |
20 | 特開2020-193227 | 外用組成物 | 2024-09-05 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 342 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.6. The most protest patent is 特開2020-193227 "外用組成物" (13 times) , and the next most protest patent is 特開2018-177763 "トラネキサム酸類配合製剤" (9 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2020-193227 | 外用組成物 | 13 times |
2 | 特開2018-177763 | トラネキサム酸類配合製剤 | 9 times |
3 | 特許7037161 | 経口組成物 | 8 times |
4 | 特開2021-161042 | 組成物 | 7 times |
5 | 特開2018-030829 | ロキソプロフェン含有の医薬製剤 | 6 times |
In the last 3 years (2021-12-01 ~ 2024-11-30), there were 381 patents Inspection from third parties. The average number of Inspection is 2.1 times. The most recently Inspection patent is 特表2021-530478 "NaV1.8を阻害するためのピリジンカルボキシアミド化合物" (Inspection day 2024-11-18) , next is 特開2022-100719 "認知機能における作業記憶向上用組成物" (Inspection day 2024-11-13) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特表2021-530478 | NaV1.8を阻害するためのピリジンカルボキシアミド化合物 | 2024-11-18 |
2 | 特開2022-100719 | 認知機能における作業記憶向上用組成物 | 2024-11-13 |
3 | 特開2022-183421 | プロスタグランジンE2産生抑制皮膚外用剤 | 2024-11-11 |
4 | 特開2023-060159 | 外用組成物 | 2024-11-08 |
5 | 特開2022-137094 | グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法 | 2024-11-07 |
6 | 特表2023-535067 | ヒトにおける呼吸器疾患の治療及び/又は予防のためのβ-ヒドロキシブチレート及び関連化合物の投与 | 2024-11-07 |
7 | 特表2022-545835 | 甲状腺眼症の治療方法 | 2024-11-07 |
8 | 特開2024-130578 | 組成物 | 2024-11-01 |
9 | 特開2020-066592 | 水性貼付剤 | 2024-11-01 |
10 | 特開2023-033865 | 口腔用組成物 | 2024-10-30 |
11 | 特開2023-011769 | アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用 | 2024-10-25 |
12 | 特開2020-193227 | 外用組成物 | 2024-10-25 |
13 | 特開2024-061831 | 抗疲労剤 | 2024-10-25 |
14 | 特許7220940 | レゾルビンE2の安定等価体 | 2024-10-22 |
15 | 特開2021-151223 | マイオカイン産生促進剤、筋出力増強剤、および筋芽細胞の分化促進剤 | 2024-10-22 |
16 | 特許6672365 | エンパグリフロジンの治療的使用 | 2024-10-18 |
17 | 特許6325084 | エンパグリフロジンの治療的使用 | 2024-10-18 |
18 | 特表2021-511827 | ミトコンドリア機能を向上させる組成物および方法 | 2024-10-17 |
19 | 特開2022-128970 | 健康増進作用のある組成物 | 2024-10-15 |
20 | 特表2022-517040 | CD38に特異的な二環式ペプチドリガンド | 2024-10-10 |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 711 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.6. The most inspection patent is 特開2020-066592 "水性貼付剤" (14 times) , and the next most inspection patent is 特開2019-210216 "皮膚外用剤又は化粧料" (13 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2020-066592 | 水性貼付剤 | 14 times |
2 | 特開2019-210216 | 皮膚外用剤又は化粧料 | 13 times |
3 | 特許6934150 | 経口組成物 | 11 times |
4 | 特開2016-084337 | 外用組成物 | 11 times |
5 | 特開2020-193227 | 外用組成物 | 10 times |
Of the patent applications filed in the last 10 years (2014-12-01 to 2024-11-30), 2,474 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.1. The most cited patent is 特許6830671 "γ−ヒドロキシ酪酸(GHB)のプロドラッグ、その組成物および使用" (28 times) , and the next most cited patent is 特表2019-530732 "免疫モジュレータとして有用な対称または半対称化合物" (27 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6830671 | γ−ヒドロキシ酪酸(GHB)のプロドラッグ、その組成物および使用 | 28 times |
2 | 特表2019-530732 | 免疫モジュレータとして有用な対称または半対称化合物 | 27 times |
3 | 特許6683886 | 薬物動態が改善された放出調節ガンマ−ヒドロキシ酪酸塩製剤 | 27 times |
4 | 特表2018-527052 | 育毛を促進するための装置、システムおよび方法 | 24 times |
5 | 特許7149276 | PD-L1内在化誘導物質としてのテトラヒドロイミダゾ[4,5-C]ピリジン誘導体 | 24 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International